Inspire Medical Systems, Inc. $INSP Shares Bought by ING Groep NV

ING Groep NV lifted its holdings in Inspire Medical Systems, Inc. (NYSE:INSP) by 554.1% during the 4th quarter, HoldingsChannel.com reports. The firm owned 88,300 shares of the company’s stock after acquiring an additional 74,800 shares during the quarter. ING Groep NV’s holdings in Inspire Medical Systems were worth $8,144,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Royal Bank of Canada grew its position in Inspire Medical Systems by 16.0% in the first quarter. Royal Bank of Canada now owns 32,769 shares of the company’s stock worth $5,220,000 after buying an additional 4,528 shares during the last quarter. Integrated Wealth Concepts LLC bought a new stake in shares of Inspire Medical Systems during the 1st quarter worth $524,000. Goldman Sachs Group Inc. grew its holdings in shares of Inspire Medical Systems by 57.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 51,422 shares of the company’s stock worth $8,190,000 after acquiring an additional 18,857 shares during the last quarter. Marshall Wace LLP raised its position in shares of Inspire Medical Systems by 3.8% during the second quarter. Marshall Wace LLP now owns 15,905 shares of the company’s stock worth $2,064,000 after purchasing an additional 577 shares during the period. Finally, Jump Financial LLC acquired a new stake in shares of Inspire Medical Systems during the second quarter worth $931,000. 94.91% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research firms recently weighed in on INSP. Stifel Nicolaus decreased their price target on Inspire Medical Systems from $70.00 to $65.00 and set a “buy” rating for the company in a research report on Tuesday, May 5th. Evercore set a $55.00 price objective on shares of Inspire Medical Systems in a research note on Tuesday, May 5th. UBS Group set a $67.00 target price on shares of Inspire Medical Systems in a report on Friday, February 13th. Robert W. Baird dropped their target price on shares of Inspire Medical Systems from $63.00 to $50.00 and set a “neutral” rating on the stock in a research report on Tuesday, May 5th. Finally, Truist Financial cut their price target on shares of Inspire Medical Systems from $64.00 to $50.00 and set a “hold” rating on the stock in a report on Tuesday, May 5th. Four equities research analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and three have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $81.84.

Inspire Medical Systems Trading Up 0.3%

Shares of Inspire Medical Systems stock opened at $41.29 on Monday. Inspire Medical Systems, Inc. has a 1 year low of $38.91 and a 1 year high of $147.03. The company has a market cap of $1.19 billion, a P/E ratio of 9.20, a P/E/G ratio of 4.25 and a beta of 0.73. The stock has a 50-day moving average price of $48.93 and a 200 day moving average price of $73.20.

Inspire Medical Systems (NYSE:INSP) last issued its earnings results on Monday, May 4th. The company reported $0.10 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.38. The company had revenue of $204.58 million for the quarter, compared to the consensus estimate of $200.04 million. Inspire Medical Systems had a return on equity of 10.35% and a net margin of 14.33%.The firm’s quarterly revenue was up 1.6% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.10 EPS. Inspire Medical Systems has set its FY 2026 guidance at 0.750-1.250 EPS. On average, equities analysts forecast that Inspire Medical Systems, Inc. will post 0.91 earnings per share for the current fiscal year.

Inspire Medical Systems Company Profile

Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company’s flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.

The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.